Adaptimmune Therapeutics PLC (ADAP)
1.10
-0.10
(-8.33%)
USD |
NASDAQ |
May 17, 16:00
1.10
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Total Return Level: 1.11 for May 17, 2024
Total Return Level Chart
Historical Total Return Level Data
Date | Value |
---|---|
May 17, 2024 | 1.11 |
May 16, 2024 | 1.20 |
May 15, 2024 | 1.24 |
May 14, 2024 | 1.15 |
May 13, 2024 | 1.17 |
May 10, 2024 | 1.12 |
May 09, 2024 | 1.14 |
May 08, 2024 | 1.14 |
May 07, 2024 | 1.10 |
May 06, 2024 | 1.15 |
May 03, 2024 | 1.19 |
May 02, 2024 | 1.19 |
May 01, 2024 | 1.21 |
April 30, 2024 | 1.19 |
April 29, 2024 | 1.15 |
April 26, 2024 | 1.075 |
April 25, 2024 | 1.06 |
April 24, 2024 | 1.08 |
April 23, 2024 | 1.14 |
April 22, 2024 | 1.01 |
April 19, 2024 | 0.9767 |
April 18, 2024 | 0.8984 |
April 17, 2024 | 0.987 |
April 16, 2024 | 1.03 |
April 15, 2024 | 1.05 |
Date | Value |
---|---|
April 12, 2024 | 1.16 |
April 11, 2024 | 1.29 |
April 10, 2024 | 1.27 |
April 09, 2024 | 1.37 |
April 08, 2024 | 1.36 |
April 05, 2024 | 1.37 |
April 04, 2024 | 1.35 |
April 03, 2024 | 1.38 |
April 02, 2024 | 1.40 |
April 01, 2024 | 1.47 |
March 28, 2024 | 1.58 |
March 27, 2024 | 1.58 |
March 26, 2024 | 1.52 |
March 25, 2024 | 1.44 |
March 22, 2024 | 1.44 |
March 21, 2024 | 1.34 |
March 20, 2024 | 1.33 |
March 19, 2024 | 1.41 |
March 18, 2024 | 1.47 |
March 15, 2024 | 1.48 |
March 14, 2024 | 1.46 |
March 13, 2024 | 1.59 |
March 12, 2024 | 1.49 |
March 11, 2024 | 1.54 |
March 08, 2024 | 1.75 |
Total Return Level Definition
The total return level allows investors to view the performance of a security inclusive of both price appreciation and dividends/distributions. Total return level is seen as the most accurate calculation that produces returns consistent with most other sources.
Total Return Level Range, Past 5 Years
0.429
Minimum
Nov 20 2023
12.10
Maximum
Jun 02 2020
3.124
Average
2.13
Median
Mar 21 2022
Total Return Level Benchmarks
Biodexa Pharmaceuticals Plc | 1.19 |
NuCana PLC | 3.57 |
Autolus Therapeutics PLC | 4.39 |
TC BioPharm (Holdings) PLC | 1.13 |
Mereo BioPharma Group PLC | 3.20 |